LY 3000328 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor targeting specific enzymes or proteins involved in cancer cell proliferation and survival. Researchers are exploring its efficacy in preclinical studies to determine its ability to halt tumor growth and induce apoptosis in cancer cells. Additionally, it is being studied for its potential to enhance the effectiveness of existing chemotherapy regimens, offering a synergistic approach to cancer treatment. Its application may extend to personalized medicine, where it could be tailored to treat cancers with specific genetic mutations or molecular profiles. Further clinical trials are necessary to validate its safety and efficacy in human patients.